This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
MONDAY, April 7, 2025 -- The association between screen time and depression see...
MONDAY, April 7, 2025 -- Artificial intelligence (AI) recommendations are more ...
MONDAY, April 7, 2025 -- The rates of respondent dissatisfaction with current h...
MONDAY, April 7, 2025 -- In a best practice guideline issued by the American Co...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
The pharma giant is wagering potentially billions of dollars on technology from ...
Last year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the mon...
Study results in a rare form of obesity could help the company expand use of Imc...
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab,...
Human medicines European public assessment report (EPAR): Mvabea, Ebola vaccine ...
As scientists across the U.S. face increasing uncertainty due to funding freezes...
Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Dat...
After launching its latest intravascular lithotripsy catheter, designed to punch...
Viatris has agreed to a settlement worth up to $335 million to resolve opioid-re...
Rhythm's Imcivree helped patients with obesity due to brain damage lose weight i...
Human medicines European public assessment report (EPAR): Fluenz, influenza vacc...
On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&...
Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tez...
Human medicines European public assessment report (EPAR): Zabdeno, ebola vaccine...
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 April 2025, European Me...
Lexeo Therapeutics has posted updated data in Friedreich ataxia patients, linkin...
New product information wording: extracts from PRAC recommendations on signals a...
Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, ...